Epigenetic dysregulation of epstein-barr virus latency and development of autoimmune disease

Advances in Experimental Medicine and Biology

Volumn 711, Issue , 2011, Pages 82-102

  Niller, Hans Helmut ^a   Wolf, Hans ^a   Ay, Eva ^b   Minarovits, Janos ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; VIRUS ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; CROSS REACTION; EBER1 GENE; EBNA1 GENE; EBNA2 GENE; EPIGENETICS; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE FUNCTION; HISTONE MODIFICATION; HUMAN; IMMUNOREACTIVITY; METHYLATION; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS GENE; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANIMAL; CPG ISLAND; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; MOLECULAR GENETICS; REVIEW; VIROLOGY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

AMINO ACID SEQUENCE; ANIMALS; AUTOIMMUNE DISEASES; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; HERPESVIRUS 4, HUMAN; HUMANS; MOLECULAR SEQUENCE DATA; VIRUS LATENCY;

EID: 79958247819     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-8216-2_7     Document Type: Article

References (185)

1. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10:803-821. (Pubitemid 38198878)
2. Niller HH, Wolf H, Minarovits J. Epstein-Barr Virus. In: Minarovits J, Gonczol E, Valyi-Nagy T, eds. Latency Strategies of Herpesviruses. New York: Springer, 2007:154-191.
3. Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 2008; 41:298-328. (Pubitemid 351593860)
4. Hadinoto V, Shapiro M, Sun CC et al. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 2009; 5:e1000496.
5. Crawford DH. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 2001; 356:461-473. (Pubitemid 32442746)
6. Hochberg D, Souza T, Catalina M et al. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol 2004; 78:5194-5204. (Pubitemid 38581471)
7. Tierney RJ, Steven N, Young LS et al. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994; 68:7374-7385. (Pubitemid 24328793)
8. Tosato G, Magrath I, Koski I et al. Activation of suppressor T-cells during Epstein-Barr-virus-induced infectious mononucleosis. N Engl J Med 1979; 301:1133-1137. (Pubitemid 10158783)
9. Moss DJ, Burrows SR, Silins SL et al. The immunology of Epstein-Barr virus infection. Philos Trans R Soc Lond B Biol Sci 2001; 356:475-488. (Pubitemid 32442747)
10. Silins SL, Sherritt MA, Silleri JM et al. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 2001; 98:3739-3744.
11. Thorley-Lawson DA, Gross A. Persistence ofthe Epstein-Barr virus and the origins ofassociated lymphomas. N Engl J Med 2004; 350:1328-1337. (Pubitemid 38375368)
12. Souza TA, Stollar BD, Sullivan JL et al. Peripheral B-cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B-cells. Proc Natl Acad Sci USA 2005; 102:18093-18098. (Pubitemid 41798507)
13. Kurth J, Spieker T, Wustrow J et al. EBV-infected B-cells in infectious mononucleosis: viral strategies for spreading in the B-cell compartment and establishing latency. Immunity 2000; 13:485-495.
14. Kurth J, Hansmann ML, Rajewsky K et al. Epstein-Barr virus-infected B-cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction. Proc Natl Acad Sci USA 2003; 100:4730-4735. (Pubitemid 36457798)
15. Roughan JE, Thorley-Lawson DA. The intersection of Epstein-Barr virus with the germinal center. J Virol 2009; 83:3968-3976.
16. Roughan JE, Torgbor C, Thorley-Lawson DA. Germinal center B-cells latently infected with Epstein-Barr virus proliferate extensively but do not increase in number. J Virol 2010; 84:1158-1168.
17. Ehlin-Henriksson B, GordonJ, Klein G. B-lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression. Immunology 2003; 108:427-430. (Pubitemid 36469679)
18. Uchida J, Yasui T, Takaoka-Shichijo Y et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 1999; 286:300-303. (Pubitemid 29484694)
19. Lenoir GM, Bornkamm G. Burkitt's Lymphoma, a human cancer model for the study of the multistep dvelopment of cancer: proposal for a new scenario. In: Klein G, ed. Advances in Viral Oncology. New York: Raven Press, 1987:173-206.
20. Araujo I, Foss HD, Hummel M et al. Frequent expansion of Epstein-Barr virus (EBV) infected cells in germinal centres of tonsils from an area with a high incidence of EBV-associated lymphoma. J Pathol 1999; 187:326-330. (Pubitemid 29064159)
21. Niller HH, Salamon D, Ilg K et al. EBV-associated neoplasms: alternative pathogenetic pathways. Med Hypotheses 2004; 62:387-391. (Pubitemid 38388901)
22. Marschall M, Leser U, Seibl R et al. Identification of proteins encoded by Epstein-Barr virus trans-activator genes. J Virol 1989; 63:938-942. (Pubitemid 19057264)
23. Sinclair AJ, Brimmell M, Shanahan F et al. Pathways of activation of the Epstein-Barr virus productive cycle. J Virol 1991; 65:2237-2244.
24. Niller HH, Salamon D, Banati F et al. The LCR of EBV makes Burkitt's lymphoma endemic. Trends Microbiol 2004; 12:495-499. (Pubitemid 39370731)
25. Pfeffer S, ZavolanM, Grasser FA et al. Identificationofvirus- encodedmicroRNAs. Science 2004; 304:734-736.
26. Cai X, Schafer A, Lu S et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2006; 2:e23.
27. Grundhoff A, Sullivan CS, Ganem D. A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA 2006; 12:733-750.
28. Zhu JY, Pfuhl T, Motsch N et al. Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. J Virol 2009; 83:3333-3341.
29. Honess RW, Gompels UA, Barrell BG et al. Deviations from expected frequencies of CpG dinucleotides in herpesvirus DNAs may be diagnostic of differences in the states of their latent genomes. J Gen Virol 1989; 70(Pt 4):837-855. (Pubitemid 19099634)
30. Robertson KD, Ambinder RF. Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood 1997; 90:4480-4484. (Pubitemid 27508453)
31. Paulson EJ, Speck SH. Differential methylation of Epstein-Barr virus latency promoters facilitates viral persistence in healthy seropositive individuals. J Virol 1999; 73:9959-9968.
32. Minarovits J, Minarovits-Kormuta S, Ehlin-Henriksson B et al. Host cell phenotype-dependent methylation patterns of Epstein-Barr virus DNA. J Gen Virol 1991; 72:1591-1599.
33. Li H, Minarovits J. Host cell-dependent expression of latent Epstein-Barr virus genomes: regulation by DNA methylation. Adv Cancer Res 2003; 89:133-156. (Pubitemid 41184281)
34. Minarovits J. Epigenotypes of latent herpesvirus genomes. Curr Top Microbiol Immunol 2006; 310:61-80. (Pubitemid 47400286)
35. Ernberg I, Falk K, Minarovits J et al. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol 1989; 70:2989-3002. (Pubitemid 19283617)
36. Minarovits J, Hu LF, Marcsek Z et al. RNA polymerase Ill-transcribed EBER 1 and 2 transcription units are expressed and hypomethylated in the major Epstein-Barr virus-carrying cell types. J Gen Virol 1992; 73:1687-1692.
37. Altiok E, Minarovits J, Hu LF et al. Host-cell-phenotype-dependent control of the BCR2/BWR1 promoter complex regulates the expression of Epstein-Barr virus nuclear antigens 2-6. Proc Natl Acad Sci USA 1992; 89:905-909.
38. Arrand JR, Rymo L. Characterization of the major Epstein-Barr virus-specific RNA in Burkitt lymphoma-derived cells. J Virol 1982; 41:376-389. (Pubitemid 12158256)
39. Felton-Edkins ZA, Kondrashov A, Karali D et al. Epstein-Barr virus induces cellular transcription factors to allow active expression of EBER genes by RNA polymerase III. J Biol Chem 2006; 281:33871-33880. (Pubitemid 46036599)
40. Lerner MR, Andrews NC, Miller G et al. Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 1981; 78:805-809. (Pubitemid 11159514)
41. Toczyski DP, Matera AG, Ward DC et al. The Epstein-Barr virus (EBV) small RNA EBER1 binds and relocalizes ribosomal protein L22 in EBV-infected human B lymphocytes. Proc Natl Acad Sci USA 1994; 91:3463-3467. (Pubitemid 24130257)
42. Clarke PA, Schwemmle M, Schickinger J et al. Binding of Epstein-Barr virus small RNA EBER-1 to the double-stranded RNA-activated protein kinase DAI. Nucleic Acids Res 1991; 19:243-248. (Pubitemid 21896965)
43. Elia A, Vyas J, Laing KG et al. Ribosomal protein L22 inhibits regulation of cellular activities by the Epstein-Barr virus small RNA EBER-1. Eur J Biochem 2004; 271:1895-1905. (Pubitemid 38657342)
44. Komano J, Maruo S, Kurozumi K et al. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol 1999; 73:9827-9831.
45. Ruf IK, Rhyne PW, Yang C et al. Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J Virol 2000; 74:10223-10228.
46. Ruf IK, Lackey KA, Warudkar S et al. Protection from interferon-induced apoptosis by epstein-barr virus small RNAs is not mediated by inhibition of PKR. J Virol 2005; 79:14562-14569. (Pubitemid 41636255)
47. Clemens MJ. Epstein-Barr virus: inhibition of apoptosis as a mechanism of cell transformation. Int J Biochem Cell Biol 2006; 38:164-169. (Pubitemid 41619446)
48. Iwakiri D, Zhou L, Samanta M et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009; 206:2091-2099.
49. Sugden B, Warren N. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol 1989; 63:2644-2649. (Pubitemid 19137542)
50. Jankelevich S, Kolman JL, Bodnar JW et al. A nuclear matrix attachment region organizes the Epstein-Barr viral plasmid inRaji cells into a single DNA domain. EMBO J 1992; 11:1165-1176.
51. Middleton T, Sugden B. Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1. J Virol 1994; 68:4067-4071. (Pubitemid 24177439)
52. White RE, Wade-Martins R, James MR. Sequences adjacent to oriP improve the persistence of Epstein-Barr virus-based episomes in B-cells. J Virol 2001; 75:11249-11252. (Pubitemid 33031594)
53. Wensing B, Stuhler A, Jenkins P et al. Variant chromatin structure of the oriP region of Epstein-Barr virus and regulation of EBER1 expression by upstream sequences and oriP. J Virol 2001; 75:6235-6241. (Pubitemid 32553158)
54. Levitskaya J, Sharipo A, Leonchiks A et al. Inhibition ofubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain ofthe Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997; 94:12616-12621. (Pubitemid 27492577)
55. Munz C. Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T-cell target. J Exp Med 2004; 199:1301-1304. (Pubitemid 38685722)
56. Lunemann JD, Edwards N, Muraro PA et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-l-specific T-cells in multiple sclerosis. Brain 2006; 129:1493-1506. (Pubitemid 43999382)
57. Rabson M, Gradoville L, Heston L et al. Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye. J Virol 1982; 44:834-844. (Pubitemid 13250545)
58. Hammerschmidt W, Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 1989; 340:393-397.
59. Ling PD, Rawlins DR, Hayward SD. The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. Proc Natl Acad Sci USA 1993; 90:9237-9241. (Pubitemid 23315758)
60. Cordier M, Calender A, Billaud M et al. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression ofB-cell activation molecules CD21 and CD23. J Virol 1990; 64:1002-1013. (Pubitemid 20087734)
61. Wang F, Tsang SF, Kurilla MG et al. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol 1990; 64:3407-3416. (Pubitemid 20219546)
62. Mannick JB, Cohen JI, Birkenbach M et al. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol 1991; 65:6826-6837.
63. Harada S, Kieff E. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol 1997; 71:6611-6618. (Pubitemid 27355319)
64. Nitsche F, Bell A, Rickinson A. Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain. J Virol 1997; 71:6619-6628. (Pubitemid 27355320)
65. Tomkinson B, Robertson E, Kieff E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 1993; 67:2014-2025. (Pubitemid 23088375)
66. Tomkinson B, Kieff E. Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol 1992; 66:2893-2903.
67. Waltzer L, Perricaudet M, Sergeant A et al. Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA. J Virol 1996; 70:5909-5915. (Pubitemid 26266803)
68. Robertson ES, Lin J, Kieff E. The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B and 3C interact with RBPJ(kappa). J Virol 1996; 70:3068-3074.
69. Chen A, Zhao B, Kieff E et al. EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol 2006; 80:10139-10150. (Pubitemid 44522607)
70. Smith P. Epstein-Barr virus complementary strand transcripts (CSTs/BARTs) and cancer. Semin Cancer Biol 2001; 11:469-476. (Pubitemid 33105026)
71. Al Mozaini M, Bodelon G, Karstegl CE et al. Epstein-Barr virus BART gene expression. J Gen Virol 2009; 90:307-316.
72. Sadler RH, Raab-Traub N. Structural analyses of the Epstein-Barr virus BamHI A transcripts. J Virol 1995; 69:1132-1141.
73. de Jesus O, Smith PR, Spender LC et al. Updated Epstein-Barr virus (EBV) DNA sequence and analysis of a promoter for the BART (CST, BARF0) RNAs of EBV. J Gen Virol 2003; 84:1443-1450. (Pubitemid 36675514)
74. He B, Raab-Traub N, Casali P et al. EBV-encoded latent membrane protein 1 cooperates with BAFF/B LyS and APRIL to induce T-cell-independent Ig heavy chain class switching. J Immunol 2003; 171:5215-5224. (Pubitemid 37432806)
75. Laux G, Dugrillon F, Eckert C et al. Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes. J Virol 1994; 68:6947-6958. (Pubitemid 24328744)
76. Sadler RH, Raab-Traub N. The Epstein-Barr virus 3.5-kilobase latent membrane protein 1 mRNA initiates from a TATA-less promoter within the first terminal repeat. J Virol 1995; 69:4577-4581.
77. Fennewald S, van Santen V, KieffE. Nucleotide sequence ofan mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol 1984; 51:411-419. (Pubitemid 14091430)
78. Rechsteiner MP, Berger C, Weber M et al. Silencing oflatent membrane protein 2B reduces susceptibility to activation oflytic Epstein-Barr virus in Burkitt's lymphoma Akata cells. J Gen Virol 2007; 88:1454-1459. (Pubitemid 46723226)
79. Rechsteiner MP, Berger C, Zauner L et al. Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection. J Virol 2008; 82:1739-1747. (Pubitemid 351206924)
80. Swanson-Mungerson M, Longnecker R. Epstein-Barr virus latent membrane protein 2A and autoimmunity. Trends Immunol 2007; 28:213-218. (Pubitemid 46667241)
81. Tsai CL, Li HP, Lu YJ et al. Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. Cancer Res 2006; 66:11668-11676.
82. Hino R, Uozaki H, Murakami N et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 2009; 69:2766-2774.
83. Xia T, O'Hara A, Araujo I et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res 2008; 68:1436-1442. (Pubitemid 351346851)
84. Lung RW, Tong JH, Sung YM et al. Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 2009; 11:1174-1184.
85. Lo AK, To KF, Lo KW et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci USA 2007; 104:16164-16169. (Pubitemid 350099379)
86. Barth S, Pfuhl T, Mamiani A et al. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res 2008; 36:666-675. (Pubitemid 351250456)
87. Choy EY, Siu KL, Kok KH et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med 2008; 205:2551-2560.
88. Nachmani D, Stern-Ginossar N, Sarid Ret al. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 2009; 5:376-385.
89. Niller HH, Wolf H, Minarovits J. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Semin Cancer Biol 2009; 19:158-164.
90. Lunemann JD, Munz C. EBV in MS: guilty by association? Trends Immunol 2009; 30:243-248
91. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003; 24:584-588. (Pubitemid 37338526)
92. Wong M, Tsao BP. Current topics in human SLE genetics. Springer Semin Immunopathol 2006; 28:97-107. (Pubitemid 46628479)
93. Hewagama A, Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun 2009; 33:3-11.
94. Brooks WH, Le Dantec C, Pers JO et al. Epigenetics and autoimmunity. J Autoimmun 2010.
95. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007; 61:288-299. (Pubitemid 46676728)
96. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007.
97. Poser CM. Notes on the pathogenesis of multiple sclerosis. Clin Neurosci 1994; 2:258-265.
98. Sutkowski N, Conrad B, Thorley-Lawson DA et al. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 2001; 15:579-589. (Pubitemid 33016443)
99. Tai AK, O'Reilly EJ, Alroy KA et al. Human endogenous retrovirus-K18 Env as a risk factor in multiple sclerosis. Mult Scler 2008; 14:1175-1180.
100. Christensen T. Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses. Rev Med Virol 2005; 15:179-211. (Pubitemid 40675909)
101. Antony JM, van Marle G, Opii W et al. Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci 2004; 7:1088-1095. (Pubitemid 41184449)
102. Alotaibi S, Kennedy J, Tellier R et al. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004; 291:1875-1879. (Pubitemid 38509501)
103. Pohl D, Krone B, Rostasy K et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006; 67:2063-2065. (Pubitemid 44967394)
104. Haahr S, Hollsberg P. Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol 2006; 16:297-310. (Pubitemid 44497311)
105. Nielsen TR, Rostgaard K, Nielsen NM et al. Multiple sclerosis after infectious mononucleosis. Arch Neurol 2007; 64:72-75. (Pubitemid 46072426)
106. Rolls AE, Giovannoni G, Constantinescu CS et al. Multiple Sclerosis, Lymphoma and Nasopharyngeal Carcinoma: The Central Role of Epstein-Barr Virus? Eur Neurol 2009; 63: 29-35.
107. DeLorenze GN, Munger KL, Lennette ET et al. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006; 63:839-844. (Pubitemid 43882291)
108. Nielsen TR, Pedersen M, Rostgaard K et al. Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals. Mult Scler 2007; 13:420-423. (Pubitemid 46706004)
109. Sundstrom P, Juto P, Wadell G et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004; 62:2277-2282. (Pubitemid 38787787)
110. Bray PF, Luka J, Bray PF et al. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 1992; 42:1798-1804.
111. Cepok S, Zhou D, Srivastava R et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005; 115:1352-1360. (Pubitemid 40629055)
112. Wucherpfennig KW, Strominger JL. Molecular mimicry in T-cell-mediated autoimmunity: viral peptides activate human T-cell clones specific for myelin basic protein. Cell 1995; 80:695-705.
113. Lang HL, Jacobsen H, Ikemizu S et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3:940-943. (Pubitemid 35154007)
114. Holmoy T, Vartdal F. Cerebrospinal fluid T-cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B-cells. J Neurovirol 2004; 10:52-56. (Pubitemid 38325109)
115. Holmoy T, Kvale EO, Vartdal F. Cerebrospinal fluid CD4+ T-cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein. J Neurovirol 2004; 10:278-283. (Pubitemid 39429938)
116. Gronen F, Ruprecht K, Weissbrich B et al. Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T-lymphocytes in patients with multiple sclerosis and healthy controls. J Neuroimmunol 2006; 180:185-192. (Pubitemid 44692331)
117. Serafini B, Rosicarelli B, Franciotta D et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204:2899-2912. (Pubitemid 350179559)
118. Ascherio A. Epstein-Barr virus in the development of multiple sclerosis. Expert Rev Neurother 2008; 8:331-333. (Pubitemid 351480900)
119. Franciotta D, Salvetti M, Lolli F et al. B-cells and multiple sclerosis. Lancet Neurol 2008; 7:852-858.
120. Salvetti M, Giovannoni G, Aloisi F. Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol 2009; 22:201-206.
121. Willis SN, Stadelmann C, Rodig SJ et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009; 132:3318-3328.
122. Peferoen LA, Lamers F, Lodder LN et al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain 2009.
123. TorkildsenO, Stansberg C, Angelskar SM et al. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathol 2009.
124. Sawalha AH, Webb R, Han S et al. Common variants within MECP2 confer risk of systemic lupus erythematosus. PLoS ONE 2008; 3:e1727.
125. Sawalha AH, Jeffries M, Webb Ret al. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun 2008; 9:368-378. (Pubitemid 351791493)
126. Xiao C, Srinivasan L, Calado DP et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9:405-414. (Pubitemid 351405110)
127. Paschos K, Smith P, Anderton E et al. Epstein-barr virus latency in B-cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim PLoS Pathog 2009; 5:e1000492
128. Harley JB, Harley IT, Guthridge JM et al. The curiously suspicious: a role for Epstein-Barr virus in lupus. Lupus 2006; 15:768-777.
129. James JA, Harley JB, Scofield RH. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18:462-467. (Pubitemid 44200328)
130. James JA, Neas BR, Moser KL et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001; 44:1122-1126. (Pubitemid 32433618)
131. James JA, Kaufman KM, Farris AD et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997; 100:3019-3026. (Pubitemid 28022839)
132. McClain MT, Heinlen LD, Dennis GJ et al. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005; 11:85-89. (Pubitemid 40215842)
133. James JA, Gross T, Scofield RH et al. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B' -derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med 1995; 181:453-461.
134. Arbuckle MR, Reichlin M, Harley JB et al. Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus. Scand J Immunol 1999; 50:447-455. (Pubitemid 29503448)
135. James JA, Harley JB. A model of peptide-induced lupus autoimmune B-cell epitope spreading is strain specific and is not H-2 restricted in mice. J Immunol 1998; 160:502-508. (Pubitemid 28116767)
136. Arbuckle MR, Gross T, Scofield RH et al. Lupus humoral autoimmunity induced in a primate model by short peptide immunization. J Investig Med 1998; 46:58-65. (Pubitemid 128452770)
137. James JA, Harley JB. Linear epitope mapping ofan Sm B/B' polypeptide. JImmunol 1992; 148:2074-2079.
138. McClain MT, Poole BD, Bruner BF et al. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum 2006; 54:360-368. (Pubitemid 43122221)
139. James JA, Scofield RH, Harley JB. Lupus humoral autoimmunity after short peptide immunization. Ann NY Acad Sci 1997; 815:124-127. (Pubitemid 27309498)
140. Sundar K, Jacques S, Gottlieb P et al. Expression ofthe Epstein-Barr virus nuclear antigen-1 (EBNA-1) in the mouse can elicit the production ofanti-dsDNA and anti-Sm antibodies. JAutoimmun 2004; 23:127-140. (Pubitemid 39485794)
141. Kaufman KM, Kirby MY, Harley JB et al. Peptide mimics of a major lupus epitope of SmB/B'. Ann NY Acad Sci 2003; 987:215-229. (Pubitemid 36584025)
142. Incaprera M, Rindi L, Bazzichi A et al. Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol 1998; 16:289-294. (Pubitemid 28219168)
143. Sabbatini A, Bombardieri S, Migliorini P. Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I. Eur J Immunol 1993; 23:1146-1152. (Pubitemid 23120179)
144. Yamazaki M, Kitamura R, Kusano S et al. Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region ofEpstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjogren's syndrome patients with pulmonary involvements. Clin Exp Immunol 2005; 139:558-568. (Pubitemid 40340156)
145. Yu SF, Wu HC, Tsai WC et al. Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. Med Microbiol Immunol 2005; 194:115-120.
146. Moon UY, Park SJ, Oh ST et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther 2004; 6:R295-R302.
147. Kang I, Quan T, NolascoH et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. JImmunol 2004; 172:1287-1294. (Pubitemid 38113792)
148. Gross AJ, Hochberg D, Rand WM et al. EBV and systemic lupus erythematosus: a new perspective. J Immunol 2005; 174:6599-6607. (Pubitemid 40705620)
149. Tsokos GC, Magrath IT, Balow JE. Epstein-Barr virus induces normal B-cell responses but defective suppressor T-cell responses in patients with systemic lupus erythematosus. J Immunol 1983; 131:1797-1801. (Pubitemid 13006895)
150. Berner BR, Tary-Lehmann M, Yonkers NL et al. Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. Cell Immunol 2005; 235:29-38. (Pubitemid 41483031)
151. Yurasov S, Wardemann H, Hammersen J et al. Defective B-cell tolerance checkpoints in systemic lupus erythematosus. JExp Med 2005; 201:703-711. (Pubitemid 40395116)
152. Wakabayashi C, Adachi T, Wienands J et al. A distinct signaling pathway used by the IgG-containing B-cell antigen receptor. Science 2002; 298:2392-2395. (Pubitemid 36014213)
153. Costenbader KH, Karlson EW. Epstein-Barr virus and rheumatoid arthritis: is there a link? Arthritis Res Ther 2006; 8:204.
154. Sawada S, Takei M, Inomata H et al. What is after cytokine-blocking therapy, a novel therapeutic target-synovial Epstein-Barr virus for rheumatoid arthritis. Autoimmun Rev 2007; 6:126-130. (Pubitemid 46187331)
155. Oliver JE, Silman AJ. Risk factors for the development ofrheumatoid arthritis. Scand JRheumatol 2006; 35:169-174. (Pubitemid 43890735)
156. Sanchez-Pernaute O, Ospelt C, Neidhart M et al. Epigenetic clues to rheumatoid arthritis. J Autoimmun 2008; 30:12-20.
157. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978; 298:869-871. (Pubitemid 8330170)
158. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30:1205-1213. (Pubitemid 18005792)
159. Jilg W, Bogedain C, Mairhofer H et al. The Epstein-Barr virus-encoded glycoprotein gp 110 (BALF 4) can serve as a target for antibody-dependent cell-mediated cytotoxicity (ADCC). Virology 1994; 202:974-977. (Pubitemid 24254913)
160. Saal JG, Krimmel M, Steidle M et al. Synovial Epstein-Barr virus
161. Dreyfus DH. Paleo-immunology: evidence consistent with insertion of a primordial herpes virus-like element in the origins of acquired immunity. PloS ONE 2009; 4:e5778.
162. Massa M, Mazzoli F, Pignatti P et al. Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis Rheum 2002; 46:2721-2729. (Pubitemid 36118937)
163. Ray CG, Gall EP, Minnich LL et al. Acute polyarthritis associated with active Epstein-Barr virus infection. JAMA 1982; 248:2990-2993. (Pubitemid 13243893)
164. Blaschke S, Schwarz G, Moneke D et al. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells and synovial membranes of patients with rheumatoid arthritis. J Rheumatol 2000; 27:866-873. (Pubitemid 30389739)
165. Balandraud N, Meynard JB, Auger I et al. Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum 2003; 48:1223-1228. (Pubitemid 36554521)
166. Takei M, Mitamura K, Fujiwara S et al. Detection of Epstein-Barr virus-encoded small RNA 1 and latent membrane protein 1 in synovial lining cells from rheumatoid arthritis patients. Int Immunol 1997; 9:739-743. (Pubitemid 27226397)
167. Agarwal V, Singh R, Chauhan S. Remission ofrheumatoid arthritis after acute disseminated varicella-zoster infection. Clin Rheumatol 2007; 26:779-780. (Pubitemid 46554092)
168. Pomponi F, Cariati R, Zancai P et al. Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. Blood 1996; 88:3147-3159. (Pubitemid 26357399)
169. Fox R, Sportsman R, Rhodes G et al. Rheumatoid arthritis synovial membrane contains a 62,000-molecular-weight protein that shares an antigenic epitope with the Epstein-Barr virus-encoded associated nuclear antigen. J Clin Invest 1986; 77:1539-1547. (Pubitemid 16047098)
170. Birkenfeld P, Haratz N, Klein G et al. Cross-reactivity between the EBNA-1 p107 peptide, collagen and keratin: implications for the pathogenesis of rheumatoid arthritis. Clin Immunol Immunopathol 1990; 54:14-25. (Pubitemid 20024665)
171. Kouri T, Petersen J, Rhodes G et al. Antibodies to synthetic peptides from Epstein-Barr nuclear antigen-1 in sera of patients with early rheumatoid arthritis and in preillness sera. J Rheumatol 1990; 17:1442-1449.
172. Baboonian C, Halliday D, Venables PJ et al. Antibodies in rheumatoid arthritis react specifically with the glycine alanine repeat sequence of Epstein-Barr nuclear antigen-1. Rheumatol Int 1989; 9:161-166. (Pubitemid 20050295)
173. Petersen J, Rhodes G, Roudier J et al. Altered immune response to glycine-rich sequences of Epstein-Barr nuclear antigen-1 in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 1990; 33:993-1000. (Pubitemid 20226353)
174. Roudier J, Petersen J, Rhodes GH et al. Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110. Proc Natl Acad Sci USA 1989; 86:5104-5108. (Pubitemid 19182241)
175. Tosato G, Steinberg AD, Blaese RM. Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med 1981; 305:1238-1243. (Pubitemid 12234844)
176. Toussirot E, Wendling D, Tiberghien P et al. Decreased T-cell precursor frequencies to Epstein-Barr virus glycoprotein Gp110 in peripheral blood correlate with disease activity and severity in patients with rheumatoid arthritis. Ann Rheum Dis 2000; 59:533-538. (Pubitemid 30445832)
177. Klatt T, Ouyang Q, Flad T et al. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr viurs in patients with rheumatoid arthritis. J Rheumatol 2005; 32:239-251. (Pubitemid 40209121)
178. David-Ameline J, Lim A, Davodeau F et al. Selection of T-cells reactive against autologous B lymphoblastoid cells during chronic rheumatoid arthritis. J Immunol 1996; 157:4697-4706. (Pubitemid 126449394)
179. Scotet E, David-Ameline J, Peyrat MA et al. T-cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J Exp Med 1996; 184:1791-1800. (Pubitemid 26404470)
180. Baeten D, Peene I, Union A et al. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 2001; 44:2255-2262. (Pubitemid 32977493)
181. Pratesi F, Tommasi C, Anzilotti C et al. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54:733-741.
182. Schellekens GA, Visser H, de Jong BA et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43:155-163. (Pubitemid 30368225)
183. Rantapaa-Dahlqvist S, de Jong BA, Berglin E et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48:2741-2749. (Pubitemid 37280601)
184. Gu SY, Huang TM, Ruan L et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995; 84:171-177.
185. Wolf HJ, Morgan AJ. Epstein-Barr Virus vaccines. In: Medveczky P, Friedman H, Bendinelli M, eds. Herpesviruses and Immunity. New York: Plenum Press, 1998:231-246.